The biopharma industry completed 52 mergers and acquisitions in the first half of 2026, signaling a dramatic resurgence in dealmaking activity after several years of relative restraint. Eli Lilly led the charge with nine separate transactions totaling more than $25 billion, cementing its position as the most acquisitive major pharmaceutical company of the year.

The numbers tell a clear story: Big Pharma is back in buying mode, armed with healthy balance sheets and an urgent need to replenish drug pipelines as blockbuster treatments approach patent expiration.

Lilly's Acquisition Spree

Eli Lilly's unprecedented buying spree has redefined expectations for pharmaceutical M&A. The Indianapolis-based drugmaker has prioritized companies with AI-driven drug discovery capabilities, betting that artificial intelligence will fundamentally compress development timelines and reduce the cost of bringing new medicines to market.

Among Lilly's major acquisitions were Kelonia Therapeutics for $7 billion and Centessa Pharmaceuticals for $7.8 billion, along with three vaccine developers acquired for a combined $3.8 billion. The strategy reflects a calculated shift away from traditional internal research and development toward buying pipeline assets that have already been validated by AI screening tools.

Lilly's $25 billion commitment represents more than half of the industry's total M&A capacity deployed in the first half of the year — a remarkable concentration of dealmaking activity in a single company.

Industry-Wide Revival

While Lilly dominated headlines, other pharmaceutical giants were equally active. Gilead Sciences committed $14.8 billion across three acquisitions, while GSK pledged $13.5 billion in its own trio of deals.

Perhaps the most notable individual transaction came from Sun Pharma, which completed the largest single acquisition of the half with its $12.6 billion purchase of women's health specialist Organon.

The breadth of activity across multiple major players suggests a fundamental shift in industry sentiment rather than isolated opportunism.

AI Changes the Calculus

The surge in M&A activity is closely tied to advances in artificial intelligence and their application to drug discovery. AI tools have dramatically reduced the cost and time required to evaluate early-stage drug candidates, making smaller biotech companies with promising pipelines more attractive acquisition targets.

For major pharmaceutical companies, acquiring these AI-native pipelines has become more attractive than building comparable capabilities internally. The result is a competitive scramble for the most promising assets, driving up valuations and accelerating deal timelines.

Therapeutic Focus Areas

Oncology continues to command the largest share of deal activity, but central nervous system and neuropsychiatric indications are attracting growing attention. The maturation of several platform technologies, combined with improved understanding of CNS disease biology, has made neuroscience a particularly active area for transactions.

Rare disease and vaccines have also drawn significant interest, reflecting both unmet medical needs and attractive commercial profiles for specialized treatments.

Looking Ahead

With $25 billion already deployed by Lilly alone and comparable activity across other major players, the second half of 2026 could see continued dealmaking momentum. Patent expirations on key revenue-generating drugs remain the primary catalyst, forcing pharmaceutical companies to acquire rather than wait for internal research programs to mature.

The implications extend beyond the pharmaceutical industry itself. Biotech companies with AI capabilities and promising clinical data have become hot targets, creating opportunities for investors and entrepreneurs in the life sciences sector.

As one industry executive noted, "M&A is back, and it's being driven by a fundamental rethinking of how we develop medicines." The first half of 2026 may be just the beginning of a sustained transformation in how the pharmaceutical industry builds its future.